It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Autism spectrum disorder (ASD) is a neurodevelopmental disorder that is characterized by impairments in social interactions and communication, restricted interests and repetitive behaviors. Several studies report a high prevalence of gastrointestinal (GI) symptoms in autistic individuals. Cumulative evidence reveals that the gut microbiota and its metabolites (especially short-chain fatty acids, SCFAs) play an important role in GI disorders and the pathogenesis of ASD. However, the composition of the gut microbiota and its association with fecal SCFAs and GI symptoms of autistic children remain largely unknown. In the present study, we sequenced the bacterial 16S rRNA gene, detected fecal SCFAs, assessed GI symptoms and analyzed the relationship between the gut microbiome and fecal SCFAs in autistic and neurotypical individuals. The results showed that the compositions of the gut microbiota and SCFAs were altered in ASD individuals. We found lower levels of fecal acetic acid and butyrate and a higher level of fecal valeric acid in ASD subjects. We identified decreased abundances of key butyrate-producing taxa (Ruminococcaceae, Eubacterium, Lachnospiraceae and Erysipelotrichaceae) and an increased abundance of valeric acid associated bacteria (Acidobacteria) among autistic individuals. Constipation was the only GI disorder in ASD children in the present study. We also found enriched Fusobacterium, Barnesiella, Coprobacter and valeric acid-associated bacteria (Actinomycetaceae) and reduced butyrate-producing taxa in constipated autistic subjects. It is suggested that the gut microbiota contributes to fecal SCFAs and constipation in autism. Modulating the gut microbiota, especially butyrate-producing bacteria, could be a promising strategy in the search for alternatives for the treatment of autism spectrum disorder.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 the Fifth Affiliated Hospital of Zhengzhou University, Department of Gastroenterology, Zhengzhou, China (GRID:grid.460069.d)
2 the Fifth Affiliated Hospital of Zhengzhou University, Department of Children Rehabilitation Medicine, Zhengzhou, China (GRID:grid.460069.d)
3 Zhengzhou University, School of Pharmaceutical Sciences, Zhengzhou, China (GRID:grid.207374.5) (ISNI:0000 0001 2189 3846)
4 the Third Affiliated Hospital of Zhengzhou University, Center of Children Psychology and Behavior, Zhengzhou, China (GRID:grid.412719.8)
5 McMaster University, Brain Body Institute, Hamilton, Canada (GRID:grid.25073.33) (ISNI:0000 0004 1936 8227)
6 the Fifth Affiliated Hospital of Zhengzhou University, Department of Children Rehabilitation Medicine, Zhengzhou, China (GRID:grid.460069.d) ; the Fifth Affiliated Hospital of Zhengzhou University, Department of Pediatrics, Zhengzhou, China (GRID:grid.460069.d)